Phase II study of neoadjuvant erlotinib in patients with stage III-N2 non-small cell lung cancer with EGFR mutations

Not Applicable

Recruiting

• Conditions: non-small cell lung cancer

• Registration Number: JPRN-UMIN000012725
• Lead Sponsor: Department of Thoracic Surgery, Tsukuba University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-02
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

1) Active lung disease such as interstitial pneumonia, pneumoconiosis, radiation pneumonitis, or medicine-induced pneumonitis 2) Prior exposure to agents directed at the HER axis (e.g. erlotinib, gefetinib, cetuximab, trastuzumab) 3) Gastrointestinal abnormalities, including active peptic ulcer or inflammatory bowel disease 4) Active ophthalmologic diseases (e.g. Sjogrens) 5) Neurological symptoms of spinal cord compression 6) Uncontrolled infections 7) History of severe heart disease 8) Serious medical complications 9) Multiple primary cancer 10) Serious psychiatric illness or psychological symptom 11) Women who are pregnant, lactating or with childbearing potential 12) Ineligible based on decision of an investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified